GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
Open accessThe DOI matches its Crossref record; 176 of the 178 references it cites were found in a registry or an index; 38 of the 156 sources its claims cite were checked for support.
Abstract
To date, non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease, affecting up to 70% of patients with diabetes. Currently, there are no specific drugs available for its treatment. Beyond their anti-hyperglycemic effect and the surprising role of cardio- and nephroprotection, GLP-1 receptor agonists (GLP-1 RAs) have shown a significant impact on body weight and clinical, biochemical and histological markers of fatty liver and fibrosis in patients with NAFLD. Therefore, GLP-1 RAs could be a weapon for the treatment of both diabetes mellitus and NAFLD. The aim of this review is to summarize the evidence currently available on the role of GLP-1 RAs in the treatment of NAFLD and to hypothesize potential future scenarios.
Overview
CoChat Summary
TL;DR
This narrative review summarizes evidence that GLP-1 receptor agonists improve weight, liver enzymes, steatosis, and steatohepatitis in NAFLD/NASH, with some signals for reduced fibrosis progression. It concludes that long-term human trials are still needed, especially for pre-existing fibrosis and HCC outcomes.
Key findings
- NAFLD is described as the most frequent liver disease, with a global estimated prevalence of 32.4% and affecting up to 70% of patients with diabetes; no specific drug treatment is currently available.
- GLP-1 RAs reduce body weight by about 1.5–6 kg or 2–7 kg depending on agent/dose, lower HbA1c by 0.8–1.9%, and are associated with a 9–16% reduction in cardiovascular events and all-cause mortality.
- In NASH trials, liraglutide achieved histological resolution of steatohepatitis in 39% vs 9% with placebo and reduced fibrosis progression (9% vs 36%, p = 0.04); semaglutide 0.4 mg/day achieved NASH resolution in 59% vs 17% with placebo and fibrosis progression in 5% vs 19%.
- Semaglutide 2.4 mg/week produced mean weight loss of 15.8% vs 6.4% with liraglutide in STEP 8, with >10% weight loss in 70.9% vs 25.6%, respectively.
Methods
- Narrative review of currently available evidence on GLP-1 RAs in NAFLD, including clinical trials, meta-analyses, observational data, and preclinical studies.
- The authors synthesize effects on body weight, hepatic cytolysis, steatosis, fibrosis, inflammation, and potential mechanisms, and discuss future dual/triple agonist perspectives.
- No systematic search strategy, formal quality assessment, or meta-analysis is described in the text.
Limitations
- The paper states that long-term trials evaluating GLP-1 RAs for reducing liver fibrosis are not currently available, and most fibrosis data come from indirect markers such as APRI, NFS, FIB-4, or liver stiffness.
- The paper states it is unknown whether benefits are direct or mediated by drug-induced weight loss, and several mechanistic hypotheses require further investigation.
- Evident from the text: this is a narrative review without a described systematic search or risk-of-bias assessment, and it relies on heterogeneous studies, including preclinical models and post hoc analyses.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
25 Valid · 3 Not valid · 81 Not checked · 13 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In fact, if GIP receptor agonists (GIP RA) are effective in stimulating insulin secretion and favoring peripheral glucose uptake, alone they are unable to influence body weight [17,163].”
§ GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives > 5. Future Perspectives
What the sources say
- Disputedcites [17] Gallwitz, 2022, The incretin/glucagon system as a target for pharmacotherapy of obesity, Obes. Rev. sourceExperimental — accuracy not yet measured
The Conclusions section of our copy states the opposite of the attributed claim: 'GIPR agonism alone has been shown to reduce bodyweight in mice with obesity, as observed with GIPR agonists with a longer half-life than endogenous GIP,' adding only that 'these agents alone may have limited efficacy.' The GIP IN OBESITY section likewise reports 'a reduction in calorie intake and bodyweight after both central and peripheral administration of GIPR agonists,' while noting the role of GIP in obesity 'remains controversial' and that GIP has no acute effect on food intake in humans. The only passage supporting a null effect is narrower — DUAL GLP-1R/GIPR AGONISTS refers to 'GIP analogues that do not alter bodyweight when administered alone to mice with diet-induced obesity' — so the flat claim that GIP receptor agonists alone cannot influence body weight is contrary to what this source says; its insulinotropic action, the sentence's other half, is confirmed (GIP IN OBESITY). (LLM, conf=0.78)
Checked by a reasoning model — may be wrong.
- Not checked yetcites [163] Finan, 2013, Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans, Sci. Transl. Med. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“Since GLP-1 RAs are able to reduce appetite and induce satiety and early post-prandial fullness, their use is associated with a significant weight loss secondary to a reduced caloric intake [24].”
§ GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives > 2. GLP-1 Receptor Agonists: Mechanisms of Action and Current Indications
What the sources say
- Supportedcites [24] Nauck, 2021, GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art, Mol. Metab. source
The 'Weight loss induced by GLP-1 RAs' section states that GLP-1/GLP-1 RA administration 'reduces appetite and prospective food consumption, increases satiety and a feeling of abdominal fullness, and limits caloric intake under conditions of ad libitum feeding' and that 'All GLP-1 RAs after longer-term treatment lead to weight loss'. The adjacent mechanism table (Table 3) adds explicitly that 'Reduced caloric intake is the main mechanism leading to weight loss with GLP-1 RAs', and the text quantifies the effect as 'robust', usually 2-7 kg in type 2 diabetes. The paraphrase therefore matches the source on all elements: appetite reduction, satiety/fullness, weight loss, and caloric-intake reduction as the mediating mechanism. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In particular, at a dosage of 2.4 mg per week, it has been shown to induce an average weight loss between 9.6% and 17.4%, as well as a reduction in waist circumference and arterial hypertension and an improvement of lipid profile [34,35,36,37,39].”
§ GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives > 3. Effects of GLP-1 Receptor Agonists on NAFLD > 3.1. Effects of GLP-1 RAs on Body Weight
What the sources say
- Partly supportedcites [34] Wilding, 2021, Once-Weekly Semaglutide in Adults with Overweight or Obesity, N. Engl. J. Med. sourceExperimental — accuracy not yet measured
STEP 1 (our copy) reports a single mean weight change at 2.4 mg once weekly, not the 9.6–17.4% range the citing sentence attributes to its cluster of references: Change in Body Weight gives −14.9% (treatment-policy estimand) and −16.9% (trial-product estimand) versus −2.4% with placebo, and the Abstract/Discussion state the headline 14.9% mean loss. That value falls inside the quoted interval, so this source supports the dose-and-weight-loss point but supplies no lower bound of 9.6% or upper bound of 17.4% — those figures evidently come from the other trials in the citation cluster. The accompanying cardiometabolic points are backed here: Other Confirmatory and Supportive Secondary End Points report waist circumference −13.54 cm vs −4.13 cm, greater systolic/diastolic blood-pressure reductions, and favourable fasting lipid changes, and the Discussion lists reductions in waist circumference, blood pressure and lipid levels. (LLM, conf=0.75)
- Not checked yetcites [35] Davies, 2021, STEP 2 Study Group. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): A randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial, Lancet source
- Partly supportedcites [36] Wadden, 2021, Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial, JAMA sourceExperimental — accuracy not yet measured
In the Co-Primary End Points section our copy reports a single trial result, not a range: at week 68 mean weight change was -16.0% with semaglutide 2.4 mg/wk vs -5.7% with placebo (Abstract likewise gives -16.0%), and -17.6% vs -5.0% for the trial product estimand. So this source supports semaglutide 2.4 mg/wk inducing a large mean weight loss at the top of the cited interval (its trial-product estimate, -17.6%, actually slightly exceeds the claimed 17.4% upper bound), but it does not establish the 9.6%-17.4% range itself — nothing in our copy gives a 9.6% figure, which must come from the other pooled trials cited alongside it ([34,35,36,37,39]). The accompanying cardiometabolic points are supported: the Discussion/Supportive Secondary End Points report greater improvements in waist circumference, diastolic blood pressure and several lipid parameters vs placebo, while noting systolic blood pressure changed similarly in both groups and participants were not selected for elevated risk factors. (LLM, conf=0.78)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Notably, in the recent STEP 8 randomized clinical trial [46], semaglutide (2.4 mg/week) achieved a mean weight loss of 15.8% after 68 weeks of treatment compared with 6.4% obtained with liraglutide.”
§ GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives > 3. Effects of GLP-1 Receptor Agonists on NAFLD > 3.1. Effects of GLP-1 RAs on Body Weight
What the sources say
- Supportedcites [46] Rubino, 2022, Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial, JAMA source
The Primary Outcome section (p. ~4) states that at week 68 the estimated mean change in body weight was -15.8% with semaglutide and -6.4% with liraglutide, and the Abstract's Results report the same figures (-15.8% vs -6.4%; difference, -9.4 percentage points; P < .001). The Introduction/Abstract confirms the regimens compared were once-weekly subcutaneous semaglutide 2.4 mg vs once-daily liraglutide 3.0 mg over 68 weeks, matching every element of the claim. (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Growing evidence supports the positive impact of GLP-1 RAs in reducing hepatic cytolysis enzymes [56,61,69,70,71,72,73,74,75,76,77,78,79,80,81] (Table 2).”
§ GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives > 3. Effects of GLP-1 Receptor Agonists on NAFLD > 3.2. Effects of GLP-1 RAs on Hepatic Cytolysis
What the sources say
- Supportedcites [56] Armstrong, 2016, Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study, Lancet source
The Introduction reports that GLP-1 analogues reduce liver enzymes in murine NASH models, and Evidence before this study reports improved liver enzymes with liraglutide in a meta-analysis of patients with type 2 diabetes. In this trial, the Results report a decrease in alanine aminotransferase over time, although the between-group difference at 48 weeks was not significant. (LLM, conf=0.90)
- Supportedcites [61] Newsome, 2021, A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis, N. Engl. J. Med. source
The Efficacy section (p. 7) reports dose-dependent reductions in liver-enzyme levels with semaglutide. The figure caption (p. 9) identifies the enzymes tracked as alanine aminotransferase and aspartate aminotransferase. This trial supports the cited claim for semaglutide in patients with NASH. (LLM, conf=0.93)
- Not checked yetcites [69] Buse, 2007, Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials, Clin. Ther. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
67 more claims · 15 with their cited sources checked
Create a free account to see all 122 claims and to verify the 118 references still open.
- It may state two separate claims as one. 46
- Probably not a substantial claim. 6
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Thus, GLP-1 and its agonists slow down the progression of NASH and may positively impact the reversal of liver fibrosis.513,514”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [513]
The cited source says what the claim attributes to it.
In the citing paper
“Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications improve health outcomes in patients with type 2 diabetes mellitus (T2DM).”
From Differences in GLP-1 RA medication adherence across place-based variables in patients with diabetes living in Wisconsin (2025) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Substantial evidence also supports the beneficial effects of the GLP-1 hormone on epicardial adipose tissue [48] and in the treatment of metabolic-associated fatty liver disease (MAFLD—formerly known as non-alcoholic fatty liver disease) [49].”
From New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists (2024) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives > 3. Effects of GLP-1 Receptor Agonists on NAFLD > 3.1. Effects of GLP-1 RAs on Body Weight
“The dose used for the treatment of obesity (2.4 mg/week) is significantly more effective in determining weight loss than that used for the treatment of T2DM (1.0 mg/week) [35].”
§ GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives > 3. Effects of GLP-1 Receptor Agonists on NAFLD > 3.1. Effects of GLP-1 RAs on Body Weight
“The maximum dose of semaglutide used for the treatment of obesity is 2.8 mg/week (0.4 mg/day), whereas the maximum dose for the treatment of T2DM is 1 mg/week.”
Citations
Cites
1 retracted
Portillo-Sanchez, P., Bril, F., Maximos, M., Lomonaco, R., Biernacki, D., Orsak, B., Subbarayan, S., Webb, A., Hecht, J., & Cusi, K. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2739 · Cited by 200
RetractedSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 1×
“2021 Wilding [34] 1961 nondiabetic obese Prospective double-blind Semaglutide vs placebo Yes Semaglutide (2.”
BackgroundEASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Autophagy regulates lipid metabolism
Singh, R., Kaushik, S., Wang, Y., Xiang, Y., Novak, I., Komatsu, M., Tanaka, K., Cuervo, A. M., & Czaja, M. J. (2009) · Nature · doi:10.1038/nature07976 · Cited by 3,975
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302 · cited 1×
“Indeed, patients with NAFLD and elevation of liver cytolysis enzymes have an increased risk of NASH and progression to cirrhosis [63].”
BackgroundThe prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis
Riazi, K., Azhari, H., Charette, J. H., Underwood, F. E., King, J. A., Afshar, E. E., Swain, M. G., Congly, S. E., Kaplan, G. G., & Shaheen, A.-A. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00165-0 · Cited by 2,246
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · cited 1×
“motility, regulating postprandial glucose homeostasis [12].”
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104 · cited 3×
“, the secretion of insulin in response to oral glucose ingestion mediated by GLP-1 and glucose-dependent insulinotropic peptide—GIP) in patients with T2DM and the significant anti-hyperglycemic action, GLP-1 RAs are strongly recommended in the management of patients with T2DM [13].”
BackgroundInfluentialTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I. M., Washington, M. K., Germanidis, G., Flaherty, J. F., Schall, R. A., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61425-1 · Cited by 1,788
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 8×
“In addition, GLP-1 RAs seem to prevent the progression of T2DM-associated renal damage [24].”
BackgroundInfluentialPharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444 · cited 1×
“2021 Rubino [37] 902 non-diabetic obese/overweight patients Prospective double-blind Semaglutide vs placebo Yes Semaglutide (2.”
BackgroundDavies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419 · cited 1×
“2021 Davies [35] 1210 insulinuntreated diabetic obese/overweight patients Prospective double-blind Semaglutide 2.”
BackgroundRandomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., & Wing, R. R. (2010) · Hepatology · doi:10.1002/hep.23276 · Cited by 1,330
Dresner, A., Laurent, D., Marcucci, M., Griffin, M. E., Dufour, S., Cline, G. W., Slezak, L. A., Andersen, D. K., Hundal, R. S., Rothman, D. L., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5001 · Cited by 1,311
Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)33041-7 · Cited by 1,277
Liraglutide and renal outcomes in type 2 diabetes
Mann, J. F. E., Ørsted, D. D., Brown-Frandsen, K., Marso, S. P., Poulter, N. R., Rasmussen, S., Tornøe, K., Zinman, B., & Buse, J. B. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616011 · Cited by 1,253
Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114 · cited 1×
“2021 Wadden [36] 611 non-diabetic obese/overweight patients Prospective double-blind Semaglutide vs placebo Yes Semaglutide (2.”
BackgroundTaylor, R. S., Taylor, R. J., Bayliss, S., Hagström, H., Nasr, P., Schattenberg, J. M., Ishigami, M., Toyoda, H., Wai-Sun Wong, V., Peleg, N., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.043 · Cited by 1,069
Rubino, D. M., Greenway, F. L., Khalid, U., O’Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., Garvey, W. T., STEP 8 Investigators, et al. (2022) · JAMA · doi:10.1001/jama.2021.23619 · Cited by 995
on behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842
Frias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815 · cited 1×
“In humans, once-weekly subcutaneous dual GLP-1R/GIPR agonist LY3298176 administration obtained greater weight loss and glucose control than dulaglutide, with an acceptable tolerability profile [166].”
BackgroundO'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., Carson, C. G., Jepsen, C. H., Kabisch, M., & Wilding, J. P. H. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31773-2 · Cited by 814
Autophagy and aging: The importance of maintaining "clean" cells
Cuervo, A. M., Bergamini, E., Brunk, U. T., Dröge, W., Ffrench, M., & Terman, A. (2005) · Autophagy · doi:10.4161/auto.1.3.2017 · Cited by 792
Pratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
Once-weekly semaglutide in adolescents with obesity
Weghuber, D., Barrett, T., Barrientos-Pérez, M., Gies, I., Hesse, D., Jeppesen, O. K., Kelly, A. S., Mastrandrea, L. D., Sørrig, R., & Arslanian, S. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2208601 · Cited by 730 · cited 2×
“2022 Weghuber [49] 201 obese adolescents Prospective double-blind Semaglutide vs placebo Yes Semaglutide (2.”
BackgroundA Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
Kelly, A. S., Auerbach, P., Barrientos-Perez, M., Gies, I., Hale, P. M., Marcus, C., Mastrandrea, L. D., Prabhu, N., & Arslanian, S. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916038 · Cited by 723
Semaglutide lowers body weight in rodents via distributed neural pathways.
Gabery, S., Salinas, C. G., Paulsen, S. J., Ahnfelt-Rønne, J., Alanentalo, T., Baquero, A. F., Buckley, S. T., Farkas, E., Fekete, C., Frederiksen, K. S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133429 · Cited by 717 · cited 1×
“It has been hypothesized that liraglutide and semaglutide act through different neurological pathways, providing the rationale for their different efficacy in inducing weight loss [54].”
BackgroundKlonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696 · cited 3×
“In fact, if GIP receptor agonists (GIP RA) are effective in stimulating insulin secretion and favoring peripheral glucose uptake, alone they are unable to influence body weight [17,163].”
BackgroundInfluentialBlundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12932 · Cited by 693
Friedman, S. L., Ratziu, V., Harrison, S. A., Abdelmalek, M. F., Aithal, G. P., Caballeria, J., Francque, S., Farrell, G., Kowdley, K. V., Craxi, A., et al. (2018) · Hepatology · doi:10.1002/hep.29477 · Cited by 671 · cited 1×
“Despite normalization of liver injury indices is an independent predictor of fibrosis improvement in patients with NASH [65], for several drugs this improvement is not associated with a significant histological and prognostic benefit [7,68].”
BackgroundIncretin-based therapies for type 2 diabetes mellitus
Lovshin, J. A., & Drucker, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.48 · Cited by 649
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Ludvik, B., Giorgino, F., Jódar, E., Frias, J. P., Fernández Landó, L., Brown, K., Bray, R., & Rodríguez, Á. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01443-4 · Cited by 639 · cited 1×
“Moreover, dual GLP-1 RA/GIP RA tirzepatide was recently confirmed to be superior to both insulin degludec and semaglutide in reducing glycosylated hemoglobin levels and body weight at all doses tested [167,168].”
BackgroundGerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31150-x · Cited by 638 · cited 1×
“Treatment with these drugs is in fact associated with a reduced decline in the estimated glomerular filtration rate (eGFR), as well as with a reduction in urinary albumin excretion and in the incidence rate of de novo albuminuria [28,29].”
BackgroundRole of leptin and adiponectin in insulin resistance
Yadav, A., Kataria, M. A., Saini, V., & Yadav, A. (2013) · Clinica Chimica Acta · doi:10.1016/j.cca.2012.12.007 · Cited by 637
on behalf of the SCALE study group, Blackman, A., Foster, G. D., Zammit, G., Rosenberg, R., Aronne, L., Wadden, T., Claudius, B., Jensen, C. B., & Mignot, E. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.52 · Cited by 583
Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation
Lingvay, I., Sumithran, P., Cohen, R. V., & le Roux, C. W. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01919-x · Cited by 581 · cited 1×
“Moreover, counter-regulatory mechanisms over time hinder weight loss, resulting in the recovery of body weight [30].”
BackgroundDing, X., Saxena, N. K., Lin, S., Gupta, N., & Anania, F. A. (2006) · Hepatology · doi:10.1002/hep.21006 · Cited by 557 · cited 3×
“It has been hypothesized that GLP-1 RAs could increase the levels of adiponectin, improving the degree of insulin resistance, with consequent reduction in liver fat accumulation [82,103,105] and a protective role against the development of fibrosis [114].”
BackgroundGupta, N. A., Mells, J., Dunham, R. M., Grakoui, A., Handy, J., Saxena, N. K., & Anania, F. A. (2010) · Hepatology · doi:10.1002/hep.23569 · Cited by 532 · cited 4×
“In particular, phosphorylation of AKT, a key effector for insulin signaling, appears to be significantly decreased, hindering the post-receptor signaling cascade downstream of insulin receptor substrate-2 (IRS-2) [112].”
BackgroundInfluentialAnti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
Lee, Y.-S., & Jun, H.-S. (2016) · Mediators of Inflammation · doi:10.1155/2016/3094642 · Cited by 530 · cited 2×
“Moreover, the long-term suppression of NASH and the favorable anti-oncogenic pathways exhibited by the GLP-1 RAs treatment could reduce the risk of de novo HCC and recurrence [100,139].”
BackgroundAgersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510
Rakipovski, G., Rolin, B., Nøhr, J., Klewe, I., Frederiksen, K. S., Augustin, R., Hecksher-Sørensen, J., Ingvorsen, C., Polex-Wolf, J., & Knudsen, L. B. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.09.004 · Cited by 509 · cited 1×
“The protective role on fibrosis progression demonstrated by GLP-1 RAs could be explained by the effect in reducing the expression of three out of five collagen genes [99].”
BackgroundPortillo-Sanchez, P., Bril, F., Maximos, M., Lomonaco, R., Biernacki, D., Orsak, B., Subbarayan, S., Webb, A., Hecht, J., & Cusi, K. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1966 · Cited by 503
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419
Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
Pocai, A., Carrington, P. E., Adams, J. R., Wright, M., Eiermann, G., Zhu, L., Du, X., Petrov, A., Lassman, M. E., Jiang, G., et al. (2009) · Diabetes · doi:10.2337/db09-0278 · Cited by 409
Svegliati‐Baroni, G., Saccomanno, S., Rychlicki, C., Agostinelli, L., De Minicis, S., Candelaresi, C., Faraci, G., Pacetti, D., Vivarelli, M., Nicolini, D., et al. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02462.x · Cited by 405
Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
Lomonaco, R., Godinez Leiva, E., Bril, F., Shrestha, S., Mansour, L., Budd, J., Portillo Romero, J., Schmidt, S., Chang, K.-L., Samraj, G., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1997 · Cited by 354
Pettinelli, P., & Videla, L. A. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2129 · Cited by 351
Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase
Ben-Shlomo, S., Zvibel, I., Shnell, M., Shlomai, A., Chepurko, E., Halpern, Z., Barzilai, N., Oren, R., & Fishman, S. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.09.032 · Cited by 328
Nahra, R., Wang, T., Gadde, K. M., Oscarsson, J., Stumvoll, M., Jermutus, L., Hirshberg, B., & Ambery, P. (2021) · Diabetes Care · doi:10.2337/dc20-2151 · Cited by 323 · cited 1×
“[173] evaluated the effects of cotadutide, a dual GLP-1 and glucagon receptor agonist, in 834 overweight/obesity and uncontrolled T2DM patients.”
BackgroundLee, Y.-S., Park, M.-S., Choung, J.-S., Kim, S.-S., Oh, H.-H., Choi, C.-S., Ha, S.-Y., Kang, Y., Kim, Y., & Jun, H.-S. (2012) · Diabetologia · doi:10.1007/s00125-012-2592-3 · Cited by 319 · cited 1×
“Treatment with GLP-1 RAs is also able to reduce macrophage infiltration of adipose tissue and inhibit inflammatory pathways in adipocytes, concurring to ameliorate insulin sensitivity [138].”
BackgroundJendle, J., Nauck, M. A., Matthews, D. R., Frid, A., Hermansen, K., Düring, M., Zdravkovic, M., Strauss, B. J., Garber, A. J., & Groups, O. B. O. T. L. A. L. S. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01158.x · Cited by 312
Bril, F., Biernacki, D. M., Kalavalapalli, S., Lomonaco, R., Subbarayan, S. K., Lai, J., Tio, F., Suman, A., Orsak, B. K., Hecht, J., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0167 · Cited by 312
Ambery, P., Parker, V. E., Stumvoll, M., Posch, M. G., Heise, T., Plum-Moerschel, L., Tsai, L.-F., Robertson, D., Jain, M., Petrone, M., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30726-8 · Cited by 298
Yoneda, M., Mawatari, H., Fujita, K., Iida, H., Yonemitsu, K., Kato, S., Takahashi, H., Kirikoshi, H., Inamori, M., Nozaki, Y., et al. (2007) · Journal of Gastroenterology · doi:10.1007/s00535-007-2060-x · Cited by 294 · cited 1×
“In addition to T2DM and increased cardiovascular risk [132], CRP is predictive of NASH in patients with NAFLD and is related to the presence and severity of liver fibrosis [133].”
BackgroundGLP-1 receptor agonists: an updated review of head-to-head clinical studies
Trujillo, J. M., Nuffer, W., & Smith, B. A. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018821997320 · Cited by 289
Ito, A., Hong, C., Rong, X., Zhu, X., Tarling, E. J., Hedde, P. N., Gratton, E., Parks, J., & Tontonoz, P. (2015) · eLife · doi:10.7554/elife.08009 · Cited by 281
Buse, J. B., Klonoff, D. C., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Maggs, D. G., & Wintle, M. E. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.01.015 · Cited by 279
Sharma, S., Mells, J. E., Fu, P. P., Saxena, N. K., & Anania, F. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025269 · Cited by 272 · cited 3×
“A further protective mechanism that could explain the effects of GLP-1 RAs in NAFLD is represented by the potential role in preventing hepatocyte apoptosis [91].”
BackgroundIslet α cells and glucagon--critical regulators of energy homeostasis
Campbell, J. E., & Drucker, D. J. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.51 · Cited by 266
Dutour, A., Abdesselam, I., Ancel, P., Kober, F., Mrad, G., Darmon, P., Ronsin, O., Pradel, V., Lesavre, N., Martin, J. C., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12680 · Cited by 262 · cited 2×
“Compared with other hypoglycemic agents, exenatide significantly reduces the hepatic triglyceride content and epicardial adipose tissue related to weight loss [88].”
BackgroundYan, J., Yao, B., Kuang, H., Yang, X., Huang, Q., Hong, T., Li, Y., Dou, J., Yang, W., Qin, G., et al. (2019) · Hepatology · doi:10.1002/hep.30320 · Cited by 260
Tan, T. M., Field, B. C. T., McCullough, K. A., Troke, R. C., Chambers, E. S., Salem, V., Gonzalez Maffe, J., Baynes, K. C. R., De Silva, A., Viardot, A., et al. (2013) · Diabetes · doi:10.2337/db12-0797 · Cited by 258
GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
Samms, R. J., Christe, M. E., Collins, K. A. L., Pirro, V., Droz, B. A., Holland, A. K., Friedrich, J. L., Wojnicki, S., Konkol, D. L., Cosgrove, R., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146353 · Cited by 256
Armstrong, M. J., Houlihan, D. D., Rowe, I. A., Clausen, W. H. O., Elbrønd, B., Gough, S. C. L., Tomlinson, J. W., & Newsome, P. N. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12149 · Cited by 250 · cited 8×
“[73] showed that the effect of GLP-1 RAs (in particular of liraglutide) in reducing the levels of liver damage biomarkers is closely related to the body weight loss and better glycemic control.”
BackgroundMethodInfluentialKillion, E. A., Wang, J., Yie, J., Shi, S. D.-H., Bates, D., Min, X., Komorowski, R., Hager, T., Deng, L., Atangan, L., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat3392 · Cited by 237 · cited 1×
“However, it has been shown in animal models that GIP RAs potentiates GLP-1-induced weight loss and reduces food intake [164,165].”
BackgroundMantovani, A., Byrne, C. D., & Targher, G. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00261-2 · Cited by 230 · cited 1×
“As discussed, GLP-1 RAs have been shown to improve liver enzymes and hepatic fat accumulation as well as promote resolution of steatohepatitis in patients with NAFLD [106].”
BackgroundPetit, J.-M., Cercueil, J.-P., Loffroy, R., Denimal, D., Bouillet, B., Fourmont, C., Chevallier, O., Duvillard, L., & Vergès, B. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2775 · Cited by 227
Cuthbertson, D. J., Irwin, A., Gardner, C. J., Daousi, C., Purewal, T., Furlong, N., Goenka, N., Thomas, E. L., Adams, V. L., Pushpakom, S. P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050117 · Cited by 226
Halawi, H., Khemani, D., Eckert, D., O'Neill, J., Kadouh, H., Grothe, K., Clark, M. M., Burton, D. D., Vella, A., Acosta, A., et al. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30285-6 · Cited by 224 · cited 2×
“In fact, GLP-1 RAs are able to delay gastric emptying and to slow intestinal motility in the gastro-intestinal tract, which enhances the feeling of early satiety at a central level [45].”
BackgroundGlucagon Receptor Signaling and Lipid Metabolism
Galsgaard, K. D., Pedersen, J., Knop, F. K., Holst, J. J., & Wewer Albrechtsen, N. J. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00413 · Cited by 218 · cited 1×
“In particular, it inhibits hepatic synthesis and promotes beta-oxidation of fatty acids [148,150] and, probably, lipolysis in adipose tissue [151].”
BackgroundJensterle, M., Rizzo, M., Haluzík, M., & Janež, A. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02153-x · Cited by 215 · cited 4×
“In contrast, the variability in interindividual response on body weight loss in patients receiving GLP-1 RAs treatment is significantly greater than the variability in glycemic control response [16].”
BackgroundInfluentialMells, J. E., Fu, P. P., Sharma, S., Olson, D., Cheng, L., Handy, J. A., Saxena, N. K., Sorescu, D., & Anania, F. A. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00274.2011 · Cited by 202
Wadden, T. A., Tronieri, J. S., Sugimoto, D., Lund, M. T., Auerbach, P., Jensen, C., & Rubino, D. (2020) · Obesity · doi:10.1002/oby.22726 · Cited by 200 · cited 1×
“2020 Wadden [42] 282 obese Prospective double-blind Liraglutide vs placebo Yes Liraglutide (3.”
BackgroundUmapathysivam, M. M., Lee, M. Y., Jones, K. L., Annink, C. E., Cousins, C. E., Trahair, L. G., Rayner, C. K., Chapman, M. J., Nauck, M. A., Horowitz, M., et al. (2014) · Diabetes · doi:10.2337/db13-0893 · Cited by 193 · cited 1×
“However, the long-term receptor stimulation by GLP-1 over time reduces the effects on gastric emptying due to the mechanisms of tachyphylaxis [55].”
BackgroundAmelioration of muscle wasting by glucagon‐like peptide‐1 receptor agonist in muscle atrophy
Hong, Y., Lee, J. H., Jeong, K. W., Choi, C. S., & Jun, H. (2019) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12434 · Cited by 188 · cited 1×
“Furthermore, GLP-1 RAs have been shown to improve muscle wasting both by suppressing myostatin expression and promoting the expression of myogenic factors, as well as through anti-inflammatory and anti-apoptotic effects [141,142].”
BackgroundNewsome, P., Francque, S., Harrison, S., Ratziu, V., Van Gaal, L., Calanna, S., Hansen, M., Linder, M., & Sanyal, A. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15316 · Cited by 186
Garvey, W. T., Birkenfeld, A. L., Dicker, D., Mingrone, G., Pedersen, S. D., Satylganova, A., Skovgaard, D., Sugimoto, D., Jensen, C., & Mosenzon, O. (2020) · Diabetes Care · doi:10.2337/dc19-1745 · Cited by 186 · cited 1×
“2020 Garvey [48] 396 obese/overweight and insulin-treated T2DM patients Prospective double-blind Liraglutide vs placebo Yes Liraglutide (3.”
BackgroundAdiponectin Antagonizes the Oncogenic Actions of Leptin in Hepatocellular Carcinogenesis
Sharma, D., Wang, J., Fu, P. P., Sharma, S., Nagalingam, A., Mells, J., Handy, J., Page, A. J., Cohen, C., Anania, F. A., et al. (2010) · Hepatology · doi:10.1002/hep.23892 · Cited by 183
Eguchi, Y., Kitajima, Y., Hyogo, H., Takahashi, H., Kojima, M., Ono, M., Araki, N., Tanaka, K., Yamaguchi, M., Matsuda, Y., et al. (2015) · Hepatology Research · doi:10.1111/hepr.12351 · Cited by 182
Effect of liraglutide on ectopic fat in polycystic ovary syndrome: Arandomized clinical trial
Frøssing, S., Nylander, M., Chabanova, E., Frystyk, J., Holst, J. J., Kistorp, C., Skouby, S. O., & Faber, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13053 · Cited by 178
GLP-1/glucagon receptor co-agonism for treatment of obesity
Sánchez-Garrido, M. A., Brandt, S. J., Clemmensen, C., Müller, T. D., DiMarchi, R. D., & Tschöp, M. H. (2017) · Diabetologia · doi:10.1007/s00125-017-4354-8 · Cited by 175
Synthetic FXR Agonist GW4064 Prevents Diet-Induced Hepatic Steatosis and Insulin Resistance
Ma, Y., Huang, Y., Yan, L., Gao, M., & Liu, D. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-0986-7 · Cited by 165
The Diabetic Cardiomyopathy: The Contributing Pathophysiological Mechanisms
Salvatore, T., Pafundi, P. C., Galiero, R., Albanese, G., Di Martino, A., Caturano, A., Vetrano, E., Rinaldi, L., & Sasso, F. C. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.695792 · Cited by 165
Self-citationFeng, W., Gao, C., Bi, Y., Wu, M., Li, P., Shen, S., Chen, W., Yin, T., & Zhu, D. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12555 · Cited by 164
Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake
Cegla, J., Troke, R. C., Jones, B., Tharakan, G., Kenkre, J., McCullough, K. A., Lim, C. T., Parvizi, N., Hussein, M., Chambers, E. S., et al. (2014) · Diabetes · doi:10.2337/db14-0242 · Cited by 159
FXR in liver physiology: Multiple faces to regulate liver metabolism
Panzitt, K., & Wagner, M. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166133 · Cited by 157
Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Capozzi, M. E., DiMarchi, R. D., Tschöp, M. H., Finan, B., & Campbell, J. E. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00117 · Cited by 153 · cited 3×
“In particular, it inhibits hepatic synthesis and promotes beta-oxidation of fatty acids [148,150] and, probably, lipolysis in adipose tissue [151].”
Backgroundvan Bloemendaal, L., Veltman, D. J., ten Kulve, J. S., Groot, P. F. C., Ruhé, H. G., Barkhof, F., Sloan, J. H., Diamant, M., & Ijzerman, R. G. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12506 · Cited by 151
Lima-Cabello, E., García-Mediavilla, M. V., Miquilena-Colina, M. E., Vargas-Castrillón, J., Lozano-Rodríguez, T., Fernández-Bermejo, M., Olcoz, J. L., González-Gallego, J., García-Monzón, C., & Sánchez-Campos, S. (2011) · Clinical Science · doi:10.1042/cs20100387 · Cited by 144
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Pouwels, P. J. W., Pieters-van den Bos, I. C., Hoekstra, T., Diamant, M., van Raalte, D. H., & Cahen, D. L. (2016) · Diabetologia · doi:10.1007/s00125-016-4100-7 · Cited by 142 · cited 2×
“Although inconsistent data is available [84,85], most studies subsequently confirmed the in vivo benefit of GLP-1 RAs on fatty liver disease [50,56–58,61,71,74,76,77,81,84–90] (Table 3).”
BackgroundResultOhki, T., Isogawa, A., Iwamoto, M., Ohsugi, M., Yoshida, H., Toda, N., Tagawa, K., Omata, M., & Koike, K. (2012) · The Scientific World Journal · doi:10.1100/2012/496453 · Cited by 139 · cited 3×
“In this regard, Ohki et al. [97] observed a significant reduction in APRI in patients treated with liraglutide, similar to those treated with pioglitazone.”
BackgroundResultInfluentialFeng, W., Bi, Y., Li, P., Yin, T., Gao, C., Shen, S., Gao, L., Yang, D., & Zhu, D. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.12888 · Cited by 139
Tang, A., Rabasa-Lhoret, R., Castel, H., Wartelle-Bladou, C., Gilbert, G., Massicotte-Tisluck, K., Chartrand, G., Olivié, D., Julien, A.-S., de Guise, J., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2548 · Cited by 133
Day, J. W., Gelfanov, V., Smiley, D., Carrington, P. E., Eiermann, G., Chicchi, G., Erion, M. D., Gidda, J., Thornberry, N. A., Tschöp, M. H., et al. (2012) · Peptide Science · doi:10.1002/bip.22072 · Cited by 133
Matikainen, N., Söderlund, S., Björnson, E., Pietiläinen, K., Hakkarainen, A., Lundbom, N., Taskinen, M., & Borén, J. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13487 · Cited by 129 · cited 2×
“2019 Matikainen [60] 22 controlled T2DM patients Prospective single-blind Liraglutide vs placebo No Similar weight loss between 16-week liraglutide 1.”
BackgroundEffects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes
Sathyanarayana, P., Jogi, M., Muthupillai, R., Krishnamurthy, R., Samson, S. L., & Bajaj, M. (2011) · Obesity · doi:10.1038/oby.2011.152 · Cited by 124 · cited 5×
“Furthermore, the addition of exenatide to pioglitazone (already known for its benefits on NAFLD) was associated with a greater reduction in hepatic fat content compared to pioglitazone monotherapy [71].”
BackgroundInfluentialExenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease
Fan, H., Pan, Q., Xu, Y., & Yang, X. (2013) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302013000900005 · Cited by 122 · cited 4×
“2013 Fan [72] 117 T2DM and NAFLD patients Prospective randomized trial Exenatide vs metformin Yes Exenatide treatment results in significant improvement in liver enzymes compared with metformin.”
BackgroundResultInfluentialReversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR
Jadhav, K., Xu, Y., Xu, Y., Li, Y., Xu, J., Zhu, Y., Adorini, L., Lee, Y. K., Kasumov, T., Yin, L., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.01.005 · Cited by 119
Nørregaard, P. K., Deryabina, M. A., Tofteng Shelton, P., Fog, J. U., Daugaard, J. R., Eriksson, P., Larsen, L. F., & Jessen, L. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13034 · Cited by 116
Bouchi, R., Nakano, Y., Fukuda, T., Takeuchi, T., Murakami, M., Minami, I., Izumiyama, H., Hashimoto, K., Yoshimoto, T., & Ogawa, Y. (2017) · Endocrine Journal · doi:10.1507/endocrj.ej16-0449 · Cited by 113
Parker, J. A., McCullough, K. A., Field, B. C. T., Minnion, J. S., Martin, N. M., Ghatei, M. A., & Bloom, S. R. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.227 · Cited by 111
Wouters, K., van Bilsen, M., van Gorp, P. J., Bieghs, V., Lütjohann, D., Kerksiek, A., Staels, B., Hofker, M. H., & Shiri-Sverdlov, R. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.01.046 · Cited by 109
Fang, Y., Ji, L., Zhu, C., Xiao, Y., Zhang, J., Lu, J., Yin, J., & Wei, L. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.602574 · Cited by 108 · cited 1×
“[108], the stimulation of GLP-1R in the liver causes a reduction in fatty acids”
BackgroundJall, S., Sachs, S., Clemmensen, C., Finan, B., Neff, F., DiMarchi, R. D., Tschöp, M. H., Müller, T. D., & Hofmann, S. M. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.02.002 · Cited by 107
Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: A case series
Kenny, P. R., Brady, D. E., Torres, D. M., Ragozzino, L., Chalasani, N., & Harrison, S. A. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.363 · Cited by 106
Non-Alcoholic Fatty Liver Disease: From Pathogenesis to Clinical Impact
Caturano, A., Acierno, C., Nevola, R., Pafundi, P. C., Galiero, R., Rinaldi, L., Salvatore, T., Adinolfi, L. E., & Sasso, F. C. (2021) · Processes · doi:10.3390/pr9010135 · Cited by 104
Self-citationMarfella, R., Sardu, C., Balestrieri, M. L., Siniscalchi, M., Minicucci, F., Signoriello, G., Calabrò, P., Mauro, C., Pieretti, G., Coppola, A., et al. (2018) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0304-3 · Cited by 97
Self-citationZhang, Y., Jiang, L., Wang, J., Wang, T., Chien, C., Huang, W., Fu, X., Xiao, Y., Fu, Q., Wang, S., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01676-5 · Cited by 96
Handy, J. A., Fu, P. P., Kumar, P., Mells, J. E., Sharma, S., Saxena, N. K., & Anania, F. A. (2011) · Biochemical Journal · doi:10.1042/bj20102148 · Cited by 95
Gao, Q., Jia, Y., Yang, G., Zhang, X., Boddu, P. C., Petersen, B., Narsingam, S., Zhu, Y.-J., Thimmapaya, B., Kanwar, Y. S., et al. (2015) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.01.018 · Cited by 93
Exendin-4 Protects against Hyperglycemia-Induced Cardiomyocyte Pyroptosis via the AMPK-TXNIP Pathway
Wei, H., Bu, R., Yang, Q., Jia, J., Li, T., Wang, Q., & Chen, Y. (2019) · Journal of Diabetes Research · doi:10.1155/2019/8905917 · Cited by 91 · cited 1×
“Beyond improving the metabolic profile, GLP-1 RAs have been shown to significantly reduce serum levels of CRP [80,134–136], IL-6 [137] and TNF-α [136].”
BackgroundRen, Q., Chen, S., Chen, X., Niu, S., Yue, L., Pan, X., Li, Z., & Chen, X. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s381546 · Cited by 91 · cited 1×
“In addition to weight loss, semaglutide has been shown to lower the intramuscular accumulation of fat and promote protidosynthesis in these mouse models, increasing both mass and muscle function [140].”
BackgroundSeko, Y., Sumida, Y., Tanaka, S., Mori, K., Taketani, H., Ishiba, H., Hara, T., Okajima, A., Umemura, A., Nishikawa, T., et al. (2017) · Hepatology Research · doi:10.1111/hepr.12837 · Cited by 89
Cusi, K., Sattar, N., García‐Pérez, L. ‐., Pavo, I., Yu, M., Robertson, K. E., Karanikas, C. A., & Haupt, A. (2018) · Diabetic Medicine · doi:10.1111/dme.13697 · Cited by 89
GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
Lee, J., Hong, S.-W., Rhee, E.-J., & Lee, W.-Y. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.4.262 · Cited by 87
Gallwitz, B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1004044 · Cited by 81 · cited 1×
“In this perspective, the possibilities of double (GLP-1 and GIP or GLP1 and glucagon) or triple (GLP-1, GIP and glucagon) receptor agonism [147,148] are the issue of recent research.”
BackgroundInteraction between sarcopenia and nonalcoholic fatty liver disease
Joo, S. K., & Kim, W. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0358 · Cited by 78
The incretin/glucagon system as a target for pharmacotherapy of obesity
Del Prato, S., Gallwitz, B., Holst, J. J., & Meier, J. J. (2022) · Obesity Reviews · doi:10.1111/obr.13372 · Cited by 77
Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin
Vanderheiden, A., Harrison, L. B., Warshauer, J. T., Adams-Huet, B., Li, X., Yuan, Q., Hulsey, K., Dimitrov, I., Yokoo, T., Jaster, A. W., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3906 · Cited by 76
Acierno, C., Caturano, A., Pafundi, P. C., Nevola, R., Adinolfi, L. E., & Sasso, F. C. (2020) · Exploration of Medicine · doi:10.37349/emed.2020.00019 · Cited by 73
Self-citationDerosa, G., Franzetti, I. G., Querci, F., Carbone, A., Ciccarelli, L., Piccinni, M. N., Fogari, E., & Maffioli, P. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03699.x · Cited by 70 · cited 1×
“Beyond improving the metabolic profile, GLP-1 RAs have been shown to significantly reduce serum levels of CRP [80,134–136], IL-6 [137] and TNF-α [136].”
BackgroundKojima, M., Takahashi, H., Kuwashiro, T., Tanaka, K., Mori, H., Ozaki, I., Kitajima, Y., Matsuda, Y., Ashida, K., Eguchi, Y., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165722 · Cited by 69 · cited 7×
“This pathway could represent one of the protective mechanisms against HCC development exerted by GLP-1 RAs.”
BackgroundInfluentialVilar‐Gomez, E., Calzadilla‐Bertot, L., Friedman, S. L., Gra‐Oramas, B., Gonzalez‐Fabian, L., Lazo‐del Vallin, S., Diago, M., & Adams, L. A. (2017) · Liver International · doi:10.1111/liv.13480 · Cited by 63
Gupta, N. A., Kolachala, V. L., Jiang, R., Abramowsky, C., Romero, R., Fifadara, N., Anania, F., Knechtle, S., & Kirk, A. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.07.015 · Cited by 60
Gluud, L. L., Knop, F. K., & Vilsbøll, T. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-005325 · Cited by 59
Jouihan, H., Will, S., Guionaud, S., Boland, M. L., Oldham, S., Ravn, P., Celeste, A., & Trevaskis, J. L. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.09.001 · Cited by 59
Samson, S. L., Gonzalez, E. V., Yechoor, V., Bajaj, M., Oka, K., & Chan, L. (2008) · Molecular Therapy · doi:10.1038/mt.2008.198 · Cited by 54
Clinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors
Varanasi, A., Patel, P., Makdissi, A., Dhindsa, S., Chaudhuri, A., & Dandona, P. (2012) · Endocrine Practice · doi:10.4158/ep11169.or · Cited by 50
Brunell, S., Toth, P., Ramirez, Cobble, Chilton, & Chiquette (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s37969 · Cited by 49
Nevola, R., Alfano, M., Pafundi, P. C., Brin, C., Gragnano, F., Calabrò, P., Adinolfi, L. E., Rinaldi, L., Sasso, F. C., & Caturano, A. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2303106 · Cited by 49
Self-citationKamiya, M., Mizoguchi, F., & Yasuda, S. (2022) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.13025 · Cited by 49
GLP-1 as a target for therapeutic intervention
Rajeev, S. P., & Wilding, J. P. H. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.08.005 · Cited by 45
Colosimo, S., Ravaioli, F., Petroni, M. L., Brodosi, L., Marchignoli, F., Barbanti, F. A., Sasdelli, A. S., Marchesini, G., & Pironi, L. (2021) · Liver International · doi:10.1111/liv.14799 · Cited by 45
Decara, J., Arrabal, S., Beiroa, D., Rivera, P., Vargas, A., Serrano, A., Pavón, F. J., Ballesteros, J., Dieguez, C., Nogueiras, R., et al. (2016) · BioFactors · doi:10.1002/biof.1295 · Cited by 42
Elvert, R., Herling, A. W., Bossart, M., Weiss, T., Zhang, B., Wenski, P., Wandschneider, J., Kleutsch, S., Butty, U., Kannt, A., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13212 · Cited by 42 · cited 1×
“In mice and non-human primates, dual GLP-1R/GCGR (glucagon receptor) agonists have been shown to induce excellent glycemic control and significantly greater weight loss than liraglutide monotherapy, increasing energy expenditure and reducing total energy intake by 60–70% [158].”
BackgroundAssociation between use of liraglutide and liver fibrosis in patients with type 2 diabetes
Tan, Y., Zhen, Q., Ding, X., Shen, T., Liu, F., Wang, Y., Zhang, Q., Lin, R., Chen, L., Peng, Y., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.935180 · Cited by 40
de Boer, S. A., Lefrandt, J. D., Petersen, J. F., Boersma, H. H., Mulder, D. J., & Hoogenberg, K. (2016) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-015-0219-8 · Cited by 39
C/EBP homologous protein modulates liraglutide-mediated attenuation of non-alcoholic steatohepatitis
Rahman, K., Liu, Y., Kumar, P., Smith, T., Thorn, N. E., Farris, A. B., & Anania, F. A. (2016) · Laboratory Investigation · doi:10.1038/labinvest.2016.61 · Cited by 39
Marchesini, G., Bugianesi, E., Burra, P., Marra, F., Miele, L., Alisi, A., Vajro, P., Masarone, M., Petta, S., Persico, M., et al. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.04.029 · Cited by 38
Self-citationExendin-4 Inhibits Hepatic Lipogenesis by Increasing β-Catenin Signaling
Seo, M. H., Lee, J., Hong, S.-W., Rhee, E.-J., Park, S. E., Park, C. Y., Oh, K. W., Park, S. W., & Lee, W.-Y. (2016) · PLOS ONE · doi:10.1371/journal.pone.0166913 · Cited by 37 · cited 1×
“In this regard, liraglutide has been shown to reduce the hepatic expression of PPAR-γ and, consequently, the intrahepatocyte accumulation of fatty acids, restoring the physiological lipid homeostasis [122,123].”
BackgroundIncretin combination therapy for the treatment of non-alcoholic steatohepatitis
Kannt, A., Madsen, A. N., Kammermeier, C., Elvert, R., Klöckener, T., Bossart, M., Haack, T., Evers, A., Lorenz, K., Hennerici, W., et al. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14035 · Cited by 37 · cited 1×
“More recently, the combination of GLP-1 Ras with GCG RA or with GIP RA in NASH murine models allowed one to achieve additional weight loss and, more importantly, to determine a greater improvement in histological NAFLD activity score compared to treatment with mono-agonists [172].”
BackgroundLiu, Y., Han, X., Bian, Z., Peng, Y., You, Z., Wang, Q., Chen, X., Qiu, D., & Ma, X. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-011-1902-9 · Cited by 35
Marchesini, G., Bugianesi, E., Burra, P., Marra, F., Miele, L., Alisi, A., Vajro, P., Masarone, M., Petta, S., Persico, M., et al. (2022) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.04.028 · Cited by 35
Self-citationYokomori, H., & Ando, W. (2020) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2019-000370 · Cited by 33
Incretin Hormones: The Link between Glycemic Index and Cardiometabolic Diseases
Salvatore, T., Nevola, R., Pafundi, P. C., Monaco, L., Ricozzi, C., Imbriani, S., Rinaldi, L., & Sasso, F. C. (2019) · Nutrients · doi:10.3390/nu11081878 · Cited by 33
Self-citationSavvidou, S., Karatzidou, K., Tsakiri, K., Gagalis, A., Hytiroglou, P., & Goulis, J. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.12.003 · Cited by 30
Piro, S., Spadaro, L., Russello, M., Spampinato, D., Oliveri, C. E., Vasquez, E., Benigno, R., Brancato, F., Purrello, F., & Rabuazzo, A. M. (2007) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2007.08.002 · Cited by 26
Antioxidant diet and genotyping as tools for the prevention of liver disease.
Francia, R. D., Rinaldi, L., Cillo, M., Varriale, E., Facchini, G., D'Aniello, C., Marotta, G., & Berretta, M. (2016) · PubMed · Cited by 25
Self-citationLiver‐related long‐term outcomes of thiazolidinedione use in persons with type 2 diabetes
Yen, F., Yang, Y., Hwu, C., Wei, J. C., Huang, Y., Hou, M., & Hsu, C. (2020) · Liver International · doi:10.1111/liv.14385 · Cited by 25
Lee, J., Hong, S.-W., Kim, M.-J., Moon, S. J., Kwon, H., Park, S. E., Rhee, E.-J., & Lee, W.-Y. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2021.1293 · Cited by 20
Nonogaki, K., & Kaji, T. (2018) · Journal of Diabetes Research · doi:10.1155/2018/6482958 · Cited by 20
Rosato, V., Ascione, A., Nevola, R., Fracanzani, A. L., Piai, G., Messina, V., Claar, E., Coppola, C., Fontanella, L., Lombardi, R., et al. (2022) · Journal of Viral Hepatitis · doi:10.1111/jvh.13617 · Cited by 17
Self-citationErrafii, K., Khalifa, O., Al-Akl, N. S., & Arredouani, A. (2022) · Biomedicines · doi:10.3390/biomedicines10051020 · Cited by 17
Regression of HCV cirrhosis: Time will tell
Garcia‐Tsao, G. (2018) · Hepatology · doi:10.1002/hep.29720 · Cited by 15
Nonogaki, K., & Kaji, T. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.08.009 · Cited by 15
Blaslov, K., Zibar, K., Bulum, T., & Duvnjak, L. S. (2013) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2013.10.013 · Cited by 14
Effect of anti-oxidant agents in patients with hepatocellular diseases.
Francia, R. D., Rinaldi, L., Troisi, A., Benedetto, F. D., & Berretta, M. (2015) · PubMed · Cited by 14
Self-citationLi, Q., Yang, Q., Han, J. D. J., Xiaohan, L. I. U., Fu, J., & Yin, J. (2022) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(22)60196-1 · Cited by 4
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“513,514 These signaling pathways suggest that GLP-1 and its receptor agonists may in fl uence the progression of NASH through multiple mechanisms, providing several potential therapeutic targets including: FOXO1, a transcription factor that plays a critical role in regulating glucose and lipid…”
BackgroundMetabolic dysfunction-associated steatotic liver disease in adults
Huang, D. Q., Wong, V. W. S., Rinella, M. E., Boursier, J., Lazarus, J. V., Yki-Järvinen, H., & Loomba, R. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00599-1 · Cited by 293
Emerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials
Popoviciu, M.-S., Păduraru, L., Yahya, G., Metwally, K., & Cavalu, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310449 · Cited by 280
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
Do, A., Zahrawi, F., & Mehal, W. Z. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01084-2 · Cited by 169
Tschöp, M., Nogueiras, R., & Ahrén, B. (2023) · Diabetologia · doi:10.1007/s00125-023-05929-0 · Cited by 92
“GLP-1 receptor agonists have also shown success in other therapeutic areas apart from type 2 diabetes and obesity, in particular for non-alcoholic fatty liver disease [104].”
Background
Metadata
- Authors
- Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C.
- Affiliations
- University of Campania "Luigi Vanvitelli" (IT)
- Corresponding author
- Sasso, Ferdinando Carlo
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-01-15
- Volume
- 24
- Issue
- 2
- Pages
- 1703
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC9865319
- OpenAlex
- W4316664733
- Cited by
- 286
- References
- 178
- Citations by year
- 2026: 77 · 2025: 108 · 2024: 75 · 2023: 26
- FWCI
- 11.13
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi del Molise (submittedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- GLP-1 receptor agonists, non-alcoholic fatty liver disease, diabetes mellitus, liver fibrosis, weight loss, cardioprotection, renal protection, hypoglycemic effect, NAFLD treatment
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Liver, Glucagon-Like Peptide 1, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.